GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates
Insulet Corp PODD
$165.35
▼ -0.20%
($-0.33)
Index member:
S&P 500
📅 Earnings This Week
Open
$164.57
Prev Close
$165.68
Day Range
$162.43 – $168.36
52W Range
$138.79 – $354.88
Market Cap
$11.45B
P/E (TTM)
38.38
Beta
1.10
EPS (TTM)
$4.30
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2007-05-15 |
| Shares Out. | 69,260,000 |
| Website | omnipod.com ↗ |
| Phone | 18668207754 |
| Employees | 5,400 |
| Revenue | $761.7M |
| Gross Profit | $529.0M |
| Net Income | $91.1M |
| Free Cash Flow | $399.9M |
| Total Assets | $2.99B |
| Total Liabilities | $1.68B |
| Equity | $1.30B |
About Insulet Corp
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Insulet Corp is a publicly traded company under the ticker symbol PODD on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
35 analysts (2026-07-01)